Inhaled Nitric Oxide Market to Generate a Revenue of US$ 426.88 Million By 2031 | Air Liquide Healthcare Bellerophon Therapeutics Beyond Air Circassia Pharmaceuticals Getinge

Global Inhaled Nitric Oxide Market is estimated to reach US$ 426.88 Mn by 2031 from US$ 246.07 Mn in 2022. The market is estimated to grow at a CAGR of 6.64% during the forecast period from 2023 to 2031.

The market for inhaled nitric oxide is projected to experience substantial growth in the coming years, primarily driven by its expanding utilization in the healthcare sector for the treatment of diverse ailments like cardiovascular, respiratory, and neurological disorders. With the continuous progression of technology and the growing recognition of the advantages associated with nitric oxide, the market is likely to witness a further surge in its growth trajectory.

A Request of this Sample Report Here- https://www.astuteanalytica.com/request-sample/inhaled-nitric-oxide-market

The demand for inhaled nitric oxide in respiratory treatment is witnessing a notable upsurge, which is driving the market growth. Apart from its approved indications, the utilization of inhaled nitric oxide has expanded to encompass various off-label uses, including its role as a rescue therapy. Notably, nitric oxide-generating drugs like nitroglycerin and sodium nitroprusside (SNP) have long been employed to lower blood pressure and treat angina pectoris.

Extensive research has been conducted to assess the effectiveness of inhaled nitric oxide in respiratory treatment across diverse patient populations, ranging from newborns to children and adults with conditions such as acute respiratory distress syndrome (ARDS). One of the most extensively studied pharmacological interventions in the past three decades, the use of inhaled nitric oxide for ARDS treatment has shown promising results. For instance, according to data from the National Center for Biotechnology Information (NCBI), the inhalation of nitric oxide at concentrations ranging from 5-20 p.p.m. for a duration of 3 to 53 days demonstrated a reduction in pulmonary arterial pressure, decreased intrapulmonary shunting, and improved arterial oxygenation, all without causing systemic vasodilation. This increasing demand is likely to significantly contribute to the market's revenue share.

Acute Respiratory Distress Syndrome (ARDS) Captured More Than Half of the Revenue Share in the Global Market

The dominance of acute respiratory distress syndrome (ARDS) in capturing over 59% of the revenue share can be due to the increasing prevalence of respiratory disorders that necessitate the use of inhaled nitric oxide for treatment.

With the incidence of ARDS on the rise, the demand for inhaled nitric oxide as a treatment option has grown significantly. Recent evidence indicates that the prevalence of ARDS among children ranges from 2.0 to 12.8 persons per 100,000 per year, highlighting the urgent need for effective therapeutic interventions.

Extensive research has been conducted on the efficacy of inhaled nitric oxide in improving oxygenation and reducing pulmonary arterial pressure in ARDS patients. While meta-analyses have demonstrated its ability to enhance oxygenation, its impact on mortality reduction remains inconclusive. Nonetheless, inhaled nitric oxide serves as a critical therapeutic option, particularly for severe ARDS cases that have not responded to other treatments, acting as a rescue therapy.

The primary goal of using inhaled nitric oxide in ARDS treatment is to diminish pulmonary arterial pressure, enhance arterial oxygenation, and promote blood flow to well-ventilated lung areas. Although the use of inhaled nitric oxide alone has shown modest and temporary improvements in oxygenation, it has not consistently shown a significant impact on mortality or a reduction in ventilator days. However, its selective pulmonary vasodilation properties make it a valuable tool in managing refractory hypoxemia associated with ARDS.

Overall, the increasing prevalence of ARDS underscores the critical role of inhaled nitric oxide as a treatment modality. While its precise impact on mortality remains uncertain, it remains an essential option for improving oxygenation and managing severe cases of ARDS. Continued research and advancements in this field will shape and refine the use of inhaled nitric oxide in the treatment of respiratory disorders.

Technological Advancement: Unwavering Opportunities for Key Players

The global inhaled nitric oxide market is experiencing significant growth, driven by technological advancements in healthcare. These advancements have revolutionized the delivery of inhaled nitric oxide, making it more convenient and accessible for patients.

One noteworthy development is the creation of portable and user-friendly devices for inhaled nitric oxide delivery. These devices are smaller and more efficient than traditional systems and cater to the needs of patients in home care settings. Their compact design and enhanced functionality have made it easier for patients to receive treatment without the need for hospital visits.

Moreover, the introduction of innovative delivery systems, such as the iNOvent® system, has further improved the precision and accuracy of inhaled nitric oxide administration. This has allowed healthcare providers to deliver the therapy with greater control and accuracy, resulting in improved patient outcomes.

Another technological advancement that has contributed to market growth is the development of nitric oxide sensors. These sensors are designed to monitor the level of nitric oxide in a patient's breath. By accurately measuring nitric oxide levels, healthcare providers can determine the optimal dosage of inhaled nitric oxide for each individual. This personalized approach enhances patient outcomes and reduces the risk of adverse events.

Breathing Innovation: North America's Continued Dominance in the Inhaled Nitric Oxide Market

North America has emerged as a robust market and a significant producer of inhaled nitric oxide, capturing an impressive revenue share of over 36.8% in 2022. With the region accounting for approximately 35% of the global supply, it plays a pivotal role in meeting the demand for this life-saving gas.

The driving force behind the increased demand for inhaled nitric oxide in North America is the high prevalence of respiratory diseases. Acute respiratory distress syndrome (ARDS), a condition affecting around 200,000 individuals annually in the United States, poses a considerable health burden due to its sudden onset of respiratory failure and associated morbidity and mortality rates. Inhaled nitric oxide has shown remarkable efficacy in improving oxygenation by dilating pulmonary blood vessels and reducing pulmonary vascular resistance. Consequently, the demand for inhaled nitric oxide in North America is projected to rise significantly, mirroring the growing prevalence of ARDS.

Pulmonary hypertension, another significant respiratory ailment impacting approximately 1% of the US population, is characterized by elevated blood pressure in the lung arteries, leading to heart failure and even death. Inhaled nitric oxide has proven instrumental in enhancing pulmonary hemodynamics and exercise capacity among patients with pulmonary hypertension. With the escalating prevalence of this condition, North America's demand for inhaled nitric oxide is anticipated to witness a notable upsurge.

Chronic obstructive pulmonary disease (COPD), a chronic respiratory disorder affecting roughly 16 million Americans, is defined by persistent airflow limitation that remains irreversible. Inhaled nitric oxide has demonstrated its effectiveness in improving lung function and reducing pulmonary hypertension in individuals with COPD. As the prevalence of COPD continues to rise, the demand for inhaled nitric oxide in North America is expected to follow suit.

For The Full Report, Please Follow This Link- https://www.astuteanalytica.com/industry-report/inhaled-nitric-oxide-market

North America's inhaled nitric oxide market stands as a beacon of hope, offering relief and innovative solutions to combat respiratory diseases. The region's substantial market share, production capabilities, and growing demand underscore its pivotal role in addressing the respiratory health needs of the population.

List of Key Companies Profiled
Air Liquide Healthcare
Bellerophon Therapeutics
Beyond Air
Circassia Pharmaceuticals
Getinge
International Biomedical
LINDE
Mallinckrodt Pharmaceuticals
Praxair (NoxBox)
SLE
Vero Biotech
Other major players
Market Segmentation Overview
By System

Cylinder Based System
Electric System
Chemical Based System
By Type

Adults
Pediatrics
By Components

Hardware
Mechanical Ventilator
Flow Sensor
Respiratory Circuits Connectors
Nitric Oxide Container
Nitric Oxide Analyzer
Inlet & Outlet Pipe
Digital Monitor
Services
Managed Services
Professional Services
Consulting
Support & Maintenance
By Applications

Pulmonary Hypertension
Tuberculosis Treatment
Malaria Treatment
Chronic Obstructive Pulmonary Applications (COPD)
Acute Respiratory Distress Syndrome (ARDS)
Others
By End User

Hospitals
Clinics
Ambulatory Centers
By Region

North America
The U.S.
Canada
Mexico
Europe
Western Europe
The UK
Germany
France
Italy
Spain
Rest of Western Europe
Eastern Europe
Poland
Russia
Rest of Eastern Europe
Asia Pacific
China
India
Japan
Australia & New Zealand
South Korea
ASEAN
Rest of Asia Pacific
Middle East & Africa (MEA)
Saudi Arabia
South Africa
UAE
Rest of MEA
South America
Argentina
Brazil
Get a Free Sample Report Here- https://www.astuteanalytica.com/request-sample/inhaled-nitric-oxide-market

About Astute Analytica

Astute Analytica is a global analytics and advisory company that has built a solid reputation in a short period, thanks to the tangible outcomes we have delivered to our clients. We pride ourselves in generating unparalleled, in-depth and uncannily accurate estimates and projections for our very demanding clients spread across different verticals. We have a long list of satisfied and repeat clients from a wide spectrum including technology, healthcare, chemicals, semiconductors, FMCG, and many more. These happy customers come to us from all across the Globe. They are able to make well-calibrated decisions and leverage highly lucrative opportunities while surmounting the fierce challenges all because we analyze for them the complex business environment, segment-wise existing and emerging possibilities, technology formations, growth estimates, and even the strategic choices available. In short, a complete package. All this is possible because we have a highly qualified, competent, and experienced team of professionals comprising of business analysts, economists, consultants, and technology experts. In our list of priorities, you-our patron come at the top. You can be sure of best cost-effective, value-added package from us, should you decide to engage with us.

𝐆𝐞𝐭 𝐢𝐧 𝐭𝐨𝐮𝐜𝐡 𝐰𝐢𝐭𝐡 𝐮𝐬

𝐏𝐡𝐨𝐧𝐞 𝐧𝐮𝐦𝐛𝐞𝐫: +𝟏𝟖𝟖𝟖𝟒𝟐𝟗𝟔𝟕𝟓𝟕

𝐄𝐦𝐚𝐢𝐥: sales@astuteanalytica.com

𝐕𝐢𝐬𝐢𝐭 𝐨𝐮𝐫 𝐰𝐞𝐛𝐬𝐢𝐭𝐞: https://www.astuteanalytica.com/

LinkedIn | Twitter | YouTube | Facebook

This release was published on openPR.